All In Biotech

Drug Trial Radar · NCT06904872

Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)

A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)

Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

May 29, 2025

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Napo Therapeutics, S.p.A.Industry
Sponsor type
Industry
First posted
Apr 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 24-week, randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety and tolerability of crofelemer in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF) without colon-in-continuity (CIC) requiring parenteral support (PS). Blinded study drug will be administered orally (or enterally) three times daily (TID) as a novel crofelemer formulation, Crofelemer Powder for Oral Solution, or a matching placebo powder formulation for oral solution. Patients will be randomized in a 1:1:1 ratio to crofelemer 3 mg/kg/dose TID, crofelemer 10 mg/kg/dose TID or placebo.

Conditions

  • Short Bowel Syndrome
  • Malabsorption Syndromes
  • Short Gut Syndrome
  • Post-Op Complication
  • Functional Gastrointestinal Disorders

Interventions

  • Crofelemer Powder for Oral SolutionDrug

    Crofelemer Powder for Oral Solution

  • Matched Placebo Powder for Oral SolutionDrug

    Matched Placebo Powder for Oral Solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: 24 weeks
  2. Safety and TolerabilityTime frame: 24 weeks
  3. Preliminary EfficacyTime frame: 24 weeks
  4. Preliminary EfficacyTime frame: 24 weeks

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Universitäatsklinik RWTH

    Aachen, Germany · Recruiting

  • Charité Universitätsmedizin

    Berlin, Germany · Recruiting

  • Universitätsklinikum

    Essen, Germany · Recruiting

  • Asklepios Klinik St. Georg

    Hamburg, Germany · Recruiting

  • Universitätsmedizin

    Rostock, Germany · Recruiting

  • Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi

    Bologna, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Federico II

    Naples, Italy · Recruiting

  • Ospedale Università di Padova

    Padova, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.